Ahmet AYAR, Seyhan Bilge KESKİN, Erhan ÇAPKIN, Murat KARKUCAK

A prospective clinical investigation of the effects of anti-TNF alpha therapy on exercise capacity in patients with ankylosing spondylitis

Background/aim: The purpose of this study was to investigate possible effects of anti-TNF alpha therapy on cardiorespiratory fitnessand physical functional capacity of patients with ankylosing spondylitis (AS).Materials and methods: Twenty-eight AS patients meeting the modified New York criteria with active disease state and an equivalentnumber of healthy individuals as the control were prospectively enrolled. Physical working capacity and aerobic exercise capacity ofthe participants were determined by using cardiopulmonary exercise tests, performed before and 4 months after initiation of anti-TNFalpha therapy.Results: The mean age of the patients was 37 ± 9.1 years, and mean duration of disease was 8.9 ± 7.6 years. Patients with AS exhibitedsignificantly lower aerobic exercise capacity (VO2peak: 21.2 ± 5.5 vs. 27.2 ± 6.6 ml/kg/min, P = 0.001), maximum power output (110.4± 34.8 vs. 153 ± 39.8 W, P = 0.0001), and exercise duration (16.3 ± 2.6 vs. 19.6 ± 2.9 min, P = 0.0001) than the healthy controls. Whenpatients were reevaluated after 4 months of anti-TNF alpha therapy, significant improvement was obtained in patients’ aerobic capacity,maximum power output, and exercise duration.Conclusion: Results from this study indicate that in addition to inflammatory parameters and quality of life index, even short-termanti-TNF alpha therapy results in significant improvement in cardiopulmonary health status as objectively reflected by peak VO2,maximum work rate, and exercise duration.

PDF

___

1. Vernon-Roberts B. Ankylosing spondylitis: pathology. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia, PA, USA: Mosby; 2003. pp. 1205-10.
2. Miller JM, Sproule BJ. Pulmonary function in ankylosing spondylitis. Am Rev Respir Dis. 1964; 90: 376-382.
3. Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009; 68: 863-867.
4. Vander Esch M, Van’t Hul AJ, Heijmans M, Dekker J. Respiratory muscle performance as a possible determinant of exercise capacity in patients with ankylosing spondylitis. Aust J Phys 2004; 50: 41-45.
5. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377: 2127-2137.
6. Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM. Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 2005; 53: 5-11.
7. van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, van der Linden S, van der Heijde D. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 2002; 47: 8-16.
8. Turan Y, Duruöz MT, Bal S, Guvenc A, Cerrahoglu L, Gurgan A. Assessment of fatigue in patients with ankylosing spondylitis. Rheumatol Int 2007; 27: 847-852.
9. Bodur H, Ataman S, Rezvani A, Buğdaycı DS, Cevik R, Birtane M, Akıncı A, Altay Z, Günaydın R, Yener M et al. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011; 20: 543-549.
10. Cakar E, Taskaynatan MA, Dincer U, Kiralp MZ, Durmus O, Ozgül A. Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol 2009; 28: 1309-1314.
11. Braun J, van den Berg R, Baraliakos X, Boehm H, BurgosVargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P et al. 2010 update of the ASAS/ EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
12. Wasserman K, Hansen JE, Sue DY, Stringer WW, Whipp BJ. Principles of Exercise Testing and Interpretation. 4th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2005.
13. Bassett DR, Howley ET. Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med Sci Sports Exerc 2000; 32: 70-84.
14. Balady G, Arena R, Sietsema KE, Myers J, Coke L, Fletcher GF. American Heart Association scientific statement: a clinician’s guide to cardiopulmonary exercise testing in adults. Circulation 2010; 122: 191-225.
15. ERS Task Force, Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, O’Donnell DE, Puente-Maestu L, Schols AM et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007; 29: 185-209.
16. Davis J, Van der Hejde D, Dougadas M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005; 53: 494-501.
17. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008; 67: 340-345.
18. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, LeirisaloRepo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-1600.
19. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, doubleblind, placebo-controlled trial. ATLAS Study Group. Arthritis Rheum 2006; 54: 2136-2146.
20. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the antiTNF-alpha antibody infliximab. Rheumatology (Oxford) 2007; 46: 1450-1453.
21. van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R; ATLAS Study Group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11: 127-145.
22. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014; 73: 710-715.
23. Capkin E, Karkucak M, Kiris A, Durmus I, Karaman K, Karaca A, Tosun M, Ayar A. Anti-TNF-α therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology (Oxford) 2012; 51: 910-914.
24. Ward MM, Kuzis S. Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 2001; 28: 315-321.
25. Machado P, Landewé R. Spondyloarthritis: Is it time to replace BASDAI with ASDAS? Nat Rev Rheumatol 2013; 9: 388-392.